Senses Disorder TRIZ Cases

Pyrazoline dione derivatives inhibit NADPH oxidase to reduce reactive oxygen species and address oxidative stress in disease treatment.

Sulfonyl compounds modulate the CB2 receptor while minimizing CB1 activity, reducing adverse effects in pain treatment.

Pentaheterocyclic benzohydroxamic compounds selectively inhibit HDAC6, reducing cytotoxicity and improving therapeutic efficacy.

Recombinant AAV vectors carrying codon-optimized RdCVF sequences block toxic retinoid metabolism to halt blindness progression.

Halogenated bisphenol ethers target constitutively active androgen receptor splice variants to overcome castration-resistant prostate cancer therapy resistance.

Combining thymosin beta 4 with citric acid inhibits polymorphonuclear leukocyte infiltration to prevent corneal ulceration.

PDE1 inhibitors blunt LPS-induced cytokine expression and enhance anti-inflammatory responses to address unmet needs in neuroinflammatory conditions.

Formula I isoquinolones selectively bind PI3Kδ and PI3Kγ to treat asthma and rheumatoid arthritis without broad-spectrum kinase inhibition.

Autologous bone-marrow cells enriched with donor mitochondria replace defective components, correcting energy deficits without HLA matching.

Human anti-IL-13 antibodies neutralize IL-13 to reduce inflammation while avoiding corticosteroid side effects.

Hexameric IgG Fc multimers block complement-dependent cytotoxicity by binding C1q, preventing astrocyte injury and demyelination in neuromyelitis optica.

Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives inhibit cathepsin A activity to modulate bradykinin levels and platelet aggregation.

Triglyceride-based otic formulations overcome the blood-labyrinth barrier to maintain effective drug concentrations in the inner ear.

Aryl dihydropyridinone compounds inhibit monoacylglycerol acyltransferase 2 to treat metabolic disorders.

A dual fucoidan composition combines antioxidant and anti-angiogenic properties in a single oral supplement.

A pharmaceutical composition comprising 2,4-disulfonyl PBN and N-acetylcysteine treats traumatic brain injury.

A topical photosensitizing agent activated by light treats age-related macular degeneration without invasive injections.

siRNA targets 11beta-HSD1 to reduce intraocular pressure, addressing neuronal damage risks in glaucoma therapy.

Electrostatic complex of neurotrophin-4 and PAMAM G6.0 dendrimer provides sustained release, overcoming insufficient duration of action in retinal treatments.

Chelating agents sequester metal ions in liquid anti-CTLA-4 formulations, preventing oxidation and aggregation that degrade shelf life.

An autophagy stimulator composition enhances cellular degradation pathways to clear misfolded proteins in the eye.

Detects protective and risk variants in the HTRA1 gene to predict wet age-related macular degeneration risk before vision loss occurs.

Oral methylglyoxal bis(guanylhydrazone) formulation replaces intravenous injection with chronic low-dose administration to reduce bone marrow toxicity.

Gradual apremilast dosage titration reduces gastrointestinal toxicity while maintaining therapeutic efficacy.

Citrate-coated cerium oxide nanoparticles penetrate ocular barriers to reach the posterior segment without aggregation.

Zinc supplementation resolves variable therapeutic outcomes by ensuring adequate cofactor levels for metalloprotease activity.

Selective Kv1.3 antagonists reduce adverse side effects by targeting activated TEM cells without suppressing the entire immune system.

Unnatural amino acid incorporation in peptidomimetics resists proteolytic cleavage, enabling oral administration for type 2 diabetes treatment.

Amyloid imaging quantifies deposition changes via specific compounds, resolving the need for invasive brain biopsies while maintaining diagnostic accuracy.

Anc80 AAV vectors resolve low transduction rates and toxicity trade-offs in inner ear gene therapy.

Tricyclic imidazo-pyrimidinone compounds reduce lysoPC production and inflammatory cytokine release to treat atherosclerosis.

Monoclonal antibodies bind Ang2 to block Tie2 interaction, activate signaling, and restore vascular stability.

Zero-order release kinetics of Tie-2 activators maintain stable therapeutic levels to reduce intraocular pressure and prevent vision loss from glaucoma.

Fused tricyclic benzimidazole derivatives inhibit human TNFα activity with high potency and specificity.

Styrenyl derivative compounds inhibit the retinoid cycle isomerization step to modulate chromophore flux and enhance retinal cell survival.